Following a White House announcement on April 2, 2026, the Trump administration has introduced a 100% tariff on patented pharmaceutical products and ingredients imported into the United States. This action follows a Section 232 investigation which concluded that current pharmaceutical import levels threaten national security.
Timeline and Key Exemptions
The implementation follows a phased schedule:
-
120 days: Compliance window for large pharmaceutical companies.
-
180 days: Compliance window for smaller drugmakers.
Despite the high baseline rate, the policy includes several mechanisms for companies to significantly reduce or eliminate these duties:
-
Trade Partners: Products from the EU, Japan, South Korea, Switzerland, and Liechtenstein face a reduced 15% tariff. Under a newly finalized agreement, UK drug exports are entirely exempt.
-
Pricing Agreements (MFN): Sixteen major drugmakers that signed “Most Favored Nation” pricing deals are granted a full exemption until January 20, 2029.
-
Onshoring Incentives: Companies committing to domestic production arrangements can secure a lower 20% tariff rate.
-
Generics and Biosimilars: Generic drugs, biosimilars, and their associated ingredients are not subject to these new duties.
-
Orphan and Specialty Drugs: Medications addressing urgent public health needs or rare diseases may be exempt if they originate from countries with existing trade deals.
Industry Impact and Criticism
The pharmaceutical sector has reacted with a mix of strategic preparation and vocal concern:
-
Large Corporations: Many have spent the past year pledging hundreds of billions of dollars in U.S. investments to mitigate the impact of potential tariffs.
-
Mid-sized Biotech Firms: The Midsized Biotech Alliance of America (MBAA) argues the policy creates an “unfair two-tiered system.” They contend that granting exemptions primarily to those who accept price controls penalizes mid-sized innovators—the companies responsible for many breakthroughs in cancer and rare diseases—who may struggle to shoulder the heavy tariff burden.